

CV

Andrei TURTOI
DR2 INSERM
Date of birth: August 1980
Place of birth: Vršac, Yugoslavia
Nationality: German/ Serbian
Marital Status: married, 1 child

• EDUCATION

2021 HDR, University of Montpellier, France.
2008 PhD Department of Genetics, Technical University Dresden, Germany.
2004 Dipl. Ing. Chemical Engineering/ University of Applied Sciences, Aachen, Germany.
2003 B.Eng. Chemical Engineering/ University of Applied Sciences, Aachen, Germany.
1999 International Baccalaureate (IB) United World Colleges, Pune, India.

• CURRENT POSITIONS

Since 11.2016 Team Leader “Tumor Microenvironment and Resistance to Treatment” Institut de Recherche en Cancérologie de Montpellier (IRCM)/ Inserm U1194, Montpellier, France. (2017, tenure INSERM position CR1; 2021 validated as INSERM Team; 2024 promoted to DR2 INSERM position)

Since 01.2019 Director of the Montpellier Alliance for Metabolism and Metabolomic Analysis, Biocampus, UMS CNRS, INSERM and University of Montpellier.

• PREVIOUS POSITIONS

2012 – 2016 FNRS Chargé de Recherche, GIGA-Cancer, Metastasis Research, Laboratory University of Liege, Liege, Belgium.
2009 – 2012 Principal Investigator, GIGA-Cancer, Metastasis Research Laboratory, University of Liege, Liege, Belgium.
2008 – 2009 Post Doctoral Fellow, Department of Chemistry, Mass Spectrometry Laboratory, University of Liege, Liege, Belgium.
2005–2008 PhD Fellow, Institute of Medicine, Laboratory of Radiation Biology, Forschungszentrum Jülich, Germany.
2003-2004 Research Fellow, Department of Marine Chemistry, Alfred Wegener Institute for Polar and Marine Research, Bremerhaven, Germany.

• TEACHING

Since 09.2022 Lecturer, CEA-Institute, Paris Saclay, France (2h/year).
Since 04.2015 Invited Lecturer at Graduate School of Medicine, University of Gunma, Maebashi, Japan (80h/year).
2017 –2021 Lecturer, École Nationale Supérieure de Chimie de Montpellier (ENSCM), Montpellier, France (10h/year).
2014 – 2016 Proteomics for Biomarker Discovery, Faculty of Medicine, International Master of Biomedical Engineering, University of Liege, Belgium (4h/year).
2014 – 2016 Targeted Cancer Therapies, Faculty of Medicine, International Master of Biomedical Engineering, University of Liege, Belgium (4h/year).

• COMMISSIONS OF TRUST

2025 – present Member, Scientific Advisory Board of EXPOSUM, Univ. of Montpellier, France

2024 – present Member of Scientific Advisory Board, GlyCanDrug, Marie-Curie DN Network.

2012 – present Scientific Evaluator, Agence Nationale de la Recherche, France

2016 Guest Editor/Special Issue, Journal of Clinical Medicine (MDPI Publishing)

2015 – 2024 Co-chair of the “Molecular Markers and Diagnosis” scientific interest group of the American Society for Investigative Pathology, Bethesda, MD, USA.

2014 – 2016 Scientific Advisory Board Member, Targetome SA, Liege, Belgium

2010 – 2012 Associate Editor, Journal of Integrated Omics, Portugal

• MEMBERSHIPS OF SCIENTIFIC SOCIETIES

Since 2015 Belgian Association for the Study of Liver Disease

Since 2012 American Society for Investigative Pathology, Bethesda, MD, USA.

2012 – 2013 Human Proteome Organization, Santa Fe, NM, USA

2010 – 2011 American Society for Mass Spectrometry, Santa Fe, NM, USA

• ORGANISATION OF SCIENTIFIC MEETINGS

2022 The 13th International Symposium of Gunma University Initiative for Advanced Research (GIAR), Translational Cancer Research – New Trends and Future Drugs, 29th of November Maebashi, Japan.

2021 The 9th International Symposium of Gunma University Initiative for Advanced Research (GIAR), Breakthroughs in Cancer Metabolism and Technological Perspectives, On Line.

2018 6th Antibody Industrial Symposium 2018 (AIS2018), 25th - 26th of June 2018 in Montpellier, France.

• FELLOWSHIPS AND AWARDS

2017 Prime d’Encadrement Doctoral et de Recherche, INSERM, France

2016 Hans-Monga Award for Excellence in Neoplasia Research, ASIP, Bethesda, MD, USA.

2015 Award of University of Liege, Liege, Belgium

2015 Research Award of the Belgian Group of Digestive Oncology, Brussels, Belgium.

2014 Nicolas Jacquet Award, Leon Fredericq Fund, Liege, Belgium.

2014 Merit Award, American Society for Investigative Pathology (ASIP), Bethesda, MD, USA.

2013 EPIT Award, American Society for Investigative Pathology (ASIP), Bethesda, MD, USA.

• INVITED TALKS (most relevant/recent)

“CAF Heterogeneity in Liver Neoplasms”, CRCT, Toulouse, France. (2022, March 11th)

“Spatial Transcriptomics of Breast Cancer”, Kyoto University, Kyoto, Japan. (2021, October 12th).

“Role of Stroma in Resistance to Tumor Progression”, Université Libre de Bruxelles, Bruxelles, Belgium. (2017, May 5th).

“Restoring the CAF Defensive Phenotype for Effective Tumor Treatment”, Kobe University Graduate School of Medicine, Kobe, Japan. (2016, September 6th).

“Advances in The Understanding of The Contribution of Tumor Heterogeneity in Malignant Progression and Therapy Resistance” 3rd International Symposium at Gunma University Graduate School of Medicine, Maebashi, Japan. (2016, February 7th).

“Unveiling the Phenotypic Heterogeneity of Liver Metastases to Overcome Resistance to Therapies”, BACR Annual Meeting, Université Libre de Bruxelles, Bruxelles, Belgium. (2016, January 30th).

• **PUBLICATIONS (most relevant/recent)**

Authored 80 articles (# citations: >3800; H-index: 39)

<https://scholar.google.com/citations?user=EiWDOVYAAAAJ&hl=en>.

<https://orcid.org/0000-0003-3813-6635>

Updated list of publications: <https://pubmed.ncbi.nlm.nih.gov/?term=turtoi+a+NOT+Jacob>